Risk factors for severe radiation-induced oral mucositis in patients with oral cancer

Soutome, Sakiko; Yanamoto, Souichi; Nishii, Mika; Kojima, Yasuyuki; Hasegawa, Takumi; Funahara, Madoka; Akashi, Mitsuru; Umeda, Masahiro

doi:10.1016/j.jds.2021.01.009

Cited by 21 publications

(14 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Xerostomia may arise from a multitude of systemic or local etiologies [2,3]. These include polypharmacy, neck and head radiotherapy and systematic diseases, such as diabetes mellitus, sarcoidosis, systemic lupus erythematosus and the autoimmune Sjögren's syndrome [4][5][6][7]. From a careful look at literature, one may easily conclude that the prevalence of xerostomia in the general population presents a significant divergence, reportedly affecting a percentage of adults ranging from 5.5 to 46% [8,9].…”

Section: Generalmentioning

confidence: 99%

A Review on the Role of Pilocarpine on the Management of Xerostomia and the Importance of the Topical Administration Systems Development

2022

View full text Add to dashboard Cite

Xerostomia is linked to an increased risk of dental caries, oral fungal infections, and speaking/swallowing difficulties, factors that may significantly degrade patients’ life, socially- or emotionally-wise. Consequently, there is an increasing interest in developing management approaches for confronting this oral condition, at which pilocarpine, a parasympathomimetic agent, plays a vital role. Although the therapeutic effects of orally administrated pilocarpine on the salivary gland flow and the symptoms of xerostomia have been proved by numerous studies, the systemic administration of this drug is affiliated with various adverse effects. Some of the typical adverse effects include sweating, nausea, vomiting, diarrhea, rhinitis, dizziness and increased urinary frequency. In this vein, new strategies to develop novel and effective dosage forms for topical (i.e., in the oral cavity) pilocarpine administration, in order for the salivary flow to be enhanced with minimal systemic manifestations, have emerged. Therefore, the purpose of the current review is to survey the literature concerning the performance of topical pilocarpine delivery systems. According to the findings, the topical delivery of pilocarpine can be regarded as the equivalent to systemic delivery of the drug, efficacy-wise, but with improved patient tolerance and less adverse effects.

show abstract

Section: Generalmentioning

confidence: 99%

A Review on the Role of Pilocarpine on the Management of Xerostomia and the Importance of the Topical Administration Systems Development

2022

View full text Add to dashboard Cite

show abstract

“…A mucosite oral consiste na inflamação dos tecidos moles da cavidade oral, apresentando sintomatologia dolorosa, ardência e desconforto. Afeta significativamente a qualidade de vida dos pacientes e, em alguns casos, dificulta a continuidade do tratamento radioterápico (Soutome et al, 2021). Ocorre na maioria dos pacientes submetidos a RT de cabeça e pescoço, devido a geração de espécies reativas de oxigênio, ocasionando a regulação positiva de citocinas pró-inflamatórias, danificando as células da mucosa e ativando vias moleculares que amplificam a região da lesão na mucosa (Kawashita et al, 2020).…”

Section: Mucosite Oralunclassified

Manifestações orais decorrentes da radioterapia de cabeça e pescoço

Binda

Rodrigues³

et al. 2021

RSD

View full text Add to dashboard Cite

O câncer de cabeça e pescoço (CPP) corresponde a tumores localizados na pele, cavidade oral, lábios, glândulas salivares, laringe, faringe, cavidade nasal, seios paranasais, meato acústico externo e ouvido médio. Acomete pessoas de ambos o sexo, porém com maior predileção para o masculino e com idade superior a 40 anos. Os fatores de riscos associados a essa malignidade são tabagismo, etilismo, sobrepeso, exposição a raios ultravioleta, sedentarismo, entre outros. A radioterapia (RT) é o tratamento mais utilizado para CPP, e consiste em diferentes formas de radiações ionizantes que atuam sobre o DNA das células malignas, a fim causar sua morte e/ou impedir sua reprodução. Entretanto, embora seja em menor proporção, devido a maior capacidade de regeneração, a RT afeta tecidos e células saudáveis, ocasionando efeitos adversos que podem afetar o tratamento oncológico e influenciar no bem-estar de saúde do paciente. Diante do exposto, esse estudo objetivou revisar a literatura acerca das manifestações orais decorrentes da radioterapia da cabeça e do pescoço e abordar as estratégias de manejo oral para radioterapia de cabeça e pescoço. Para a construção deste artigo foi feito um levantamento bibliográfico nas bases de dados SciVerse Scopus, Scientific Eletronic Library Online (Scielo), U.S. National Library of Medicine (PUBMED) e ScienceDirect, usando o gerenciador de referências Mendeley. Os artigos foram coletados no período de maio a agosto de 2021 e contemplados entre os anos de 2015 a 2021. A partir da revisão narrativa da literatura, observou-se que as manifestações orais decorrentes da radioterapia de cabeça e pescoço xerostomia, mucosite oral, osteorradionecrose, trismo e disgeusia. Levando em consideração as grandes incidências de CPP, é de extrema importância que os profissionais da saúde estejam familiarizados com as complicações advindas de tratamentos oncológicos.

show abstract

“…Clinical risk factors for radiation-induced mucositis have been studied. Treatment with pilocarpine has been suggested to reduce the risk of severe mucositis in oral cancer patients [ 3 ]. Oral hygiene has been significantly associated with radiation-induced oral mucositis [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

Predictive Risk Factors Associated with Severe Radiation-Induced Mucositis in Nasopharyngeal or Oropharyngeal Cancer Patients: A Retrospective Study

2022

View full text Add to dashboard Cite

Radiation-induced mucositis in head and neck cancer patients generates difficulties in eating and swallowing, and may influence treatment tolerance, compliance, and quality of life. However, predictive factors have not been studied in detail. Thus, the aim of this study was to describe the association between pre-radiotherapy clinical factors and the incidence of severe radiation-induced mucositis in nasopharyngeal or oropharyngeal cancer patients. This retrospective study included all patients with definitive radiotherapy or chemoradiotherapy for nasopharyngeal or oropharyngeal cancer between July 2011 and June 2021 in a single center. The eligibility criteria included patients who received oral management during radiotherapy. Exclusion criteria was patients who received postoperative radiotherapy. The data were acquired from the medical records of patients. One hundred patients were included in this retrospective study. Grade 3 radiation-induced mucositis occurred in 47 patients (47%). Lymphocyte count was significantly associated with grade 3 mucositis (OR = 0.40; 95% CI = 0.19–0.86; p = 0.018). It is suggested that pre-radiation lower lymphocyte counts are a predictive risk factor for severe mucositis in patients who undergo definitive radiotherapy or chemoradiotherapy for nasopharyngeal or oropharyngeal cancer

show abstract

Risk factors for severe radiation-induced oral mucositis in patients with oral cancer

Cited by 21 publications

References 10 publications

A Review on the Role of Pilocarpine on the Management of Xerostomia and the Importance of the Topical Administration Systems Development

A Review on the Role of Pilocarpine on the Management of Xerostomia and the Importance of the Topical Administration Systems Development

Manifestações orais decorrentes da radioterapia de cabeça e pescoço

Predictive Risk Factors Associated with Severe Radiation-Induced Mucositis in Nasopharyngeal or Oropharyngeal Cancer Patients: A Retrospective Study

Contact Info

Product

Resources

About